Iskra was appointed Executive Vice-President (EVP), Vaccines & Immune Therapies Unit in November 2021, and is responsible for leading all COVID-19 therapy area activities, including R&D, commercial, medical, as well as AstraZeneca’s global infectious disease teams. Prior to this role, Iskra was EVP for the Europe & Canada region (for which she retains responsibility until the announcement of a successor) and has been a member of AstraZeneca’s Senior Executive Team (SET) since 2017.
Having trained as a Doctor of dental medicine at the Medical University of Zagreb, Croatia, Iskra joined AstraZeneca in 2001. During this time, Iskra has held a variety of in-market, regional sales and marketing and general management roles, including Head of Specialty Care, Central & Eastern Europe, Middle East and Africa.
In 2012 she joined AstraZeneca Russia as Marketing Director, before being appointed General Manager in 2014. Subsequently, in 2016 Iskra was made Area Vice-President for Russia and Eurasia, before her appointment as EVP, Europe in April 2017, and the later expansion of this role to Europe & Canada in 2019.
Iskra has an International Executive MBA in Business and Leadership from the IEDC-Bled School of Management, Slovenia.
In the global response to the COVID-19 pandemic, we saw unparalleled collaboration between academia, government, industry and regulators. The result was billions of vaccine doses develope...
This week AstraZeneca will bring together current and former health ministers, former world leaders, government experts, academics, and private sector partners for a global Healthcare Sys...
